Guidelines for the Determination of Brain Death in Infants and Children: An Update of the 1987 Task Force Recommendations the Society of Critical Care Medicine, Section on…

1. Effects of Renal Disease on Pharmacokinetics Juan J. L. Lertora, M.D., Ph.D. DirectorClinical Pharmacology Program Office of Clinical Research Trainingand Medical Education…

1. New Oral AnticoagulantsWho Gets What for Atrial Fibrillation andVenous Thromboembolism?Kathryn Hassell, MDProfessor of Medicine, Division of HematologyUniversity of Colorado…

1. Nicotine safety in the context of e-cigarette use and tobacco dependenceJacques Le Houezec Consultant in Public Health, Tobacco Dependence Amzer Glas, Rennes & Special…

1. The Current State of Pharmacogenomics Marti Larriva PharmD Candidate, Class of 2014 University of Arizona 2. Objectives Discuss background and relevance of pharmacogenomics…

Slide 1Overview of Overview of Sheryl Murphy, MS, RD Medical Affairs GlaxoSmithKline Slide 2 Agenda Overview – Rx History and Clinical Experience 60 mg Efficacy and Safety…

Slide 11 Pharmacometrics Impact on FDA Decisions & Recommendations: Past, Present & Future Bob Powell, PharmD Director (2/05-1/07), Pharmacometrics, OCP Office of…

Slide 1Bridging Studies Global Development W. Joe Shih Biostatistics Dept UMDNJ-School of Public Health Sept. 29, 2006 FDA/Industry Conference, Washington D.C. Slide 2 Clarification…

Slide 1Effects of Renal Disease on Pharmacokinetics Juan J. L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program Office of Clinical Research Training and Medical…

Slide 1DOSE- AND TIME- DEPENDENT PHARMACOKINETICS Slide 2 CAUSES OF DOSE- OR TIME-DEPENDENT KINETICS PROCESS EXAMPLEPARAMETER Saturable gut wall transport riboflavin F Saturable…